Coronavirus disease 2019 (COVID-19), first recognized in Wuhan, China, was recently declared a global pandemic by the World Health Organization (WHO). Advanced age and comorbid disease, well-known characteristics in the solid tumor population, have been reported as risk factors for severe disease and death. Cancer-related immunosuppression and its treatments also seem to play an active role in the prognosis, response, and clinical outcomes of these patients. The most effective combination therapy for COVID-19 is still under investigation, and the use of corticosteroids is controversial. Although, as a group, metastatic cancer patients are often considered not to be good candidates for ICU treatment, the individual prognosis should always come into consideration, even in a context of high pressure on medical facilities. We report the case of a stage IV prostate cancer patient infected with SARS-CoV-2 who required ICU admission and recovered from COVID-19 infection. Further studies are needed in order to identify accurate clinical prognostic criteria and provide the best treatment for these challenging patients.
COVID-19, SARS-CoV-2, Cancer, Critical care, Treatment Outcome
World Health Organization (WHO).
Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance. Vol.1-2. Geneva: WHO; 2020. p. 1-21.
LiangW, GuanW, ChenR, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.